Rivera, F. B. et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am. J. Prevent. Cardiol. 18, 100679 (2024).

Article  Google Scholar 

Zheng, Z. et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct. Target. Ther. 9, 234 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Drucker, D. J. GLP-1 physiology informs the pharmacotherapy of obesity. Mol. Metab. 57, 101351 (2022).

Article  CAS  PubMed  Google Scholar 

Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).

Article  CAS  PubMed  Google Scholar 

Campbell, J. E. et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 35, 1519–1529 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park, J. S., Kim, K. S. & Choi, H. J. Glucagon-like peptide-1 and hypothalamic regulation of satiation: cognitive and neural insights from human and animal studies. Diabetes Metab. J. 49, 333–347 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Nevola, R. et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wong, H. J. et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care 48, 292–300 (2025).

Article  CAS  PubMed  Google Scholar 

Pan, X. H. et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity 32, 840–856 (2024).

Article  CAS  PubMed  Google Scholar 

Ibrahim, M. et al. Obesity and its management in primary care setting. J. Diabetes Complications 39, 109045 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).

Article  CAS  PubMed  Google Scholar 

Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).

Article  CAS  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity. NICE https://www.nice.org.uk/consultations/1621/1/recommendations (2022).

Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427–437 (2025).

Article  CAS  PubMed  Google Scholar 

Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15–28 (2025).

Article  CAS  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774–785 (2022).

Article  CAS  PubMed  Google Scholar 

Potter, K. J., Phinney, J., Kulai, T. & Munro, V. Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Can. Assoc. Gastroenterol. 8, 47–57 (2025).

Article  PubMed  PubMed Central  Google Scholar 

Hartman, M. L. et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43, 1352–1355 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, B. et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes. Metab. 15, 737–749 (2013).

Article  CAS  PubMed  Google Scholar 

Yao, H. et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384, e076410076410 (2024).

Article  Google Scholar 

Li, M. et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep 48, zsae280 (2025).

Article  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. Diabetes Care 48, S207–S238 (2025).

Article  Google Scholar 

American Diabetes Association Professional Practice Committee. 8 Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care 48, S167–S180 (2025).

Article  Google Scholar 

Anson, M. et al. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia 66, 1869–1881 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen, N., Yeung, A. & Jenkins, A. Real-world experience of adjunct weekly semaglutide in type 1 diabetes. Is it worth it? Diabetes Res. Clin. Pract. 219, 111979 (2025).

Article  PubMed  Google Scholar 

Mahase, E. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. BMJ 386, q1645 (2024).

Article  PubMed  Google Scholar 

Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I. & Mannucci, E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res. Clin. Pract. 103, 269–275 (2014).

Article  CAS  PubMed  Google Scholar 

Bethel, M. A. et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44, 290–296 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P. & Rothberg, M. B. Early- and later-stage persistence with antiobesity medications: a retrospective cohort study. Obesity 32, 486–493 (2024).

Article  PubMed  Google Scholar 

Lim, C. E., Pasternak, B., Eliasson, B. & Ueda, P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia 68, 1680–1695 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. JAMA Netw. Open 7, e24131723172 (2024).

Article  Google Scholar 

Rodriguez, P. J. et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw. Open 8, e245734957349 (2025).

Article  Google Scholar 

Rodriguez, P. J. et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern. Med. 184, 1056–1064 (2024).

Article  CAS  PubMed  Google Scholar 

Durden, E., Liang, M., Fowler, R., Panton, U. H. & Mocevic, E. The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. J. Manag. Care Spec. Pharm. 25, 669–680 (2019).